- Home
- YCBD vs NCNA Comparison
YCBD vs NCNA Comparison
Compare YCBD & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- NCNA
- Stock Information
- Founded
- YCBD 2015
- NCNA 1997
- Country
- YCBD United States
- NCNA United Kingdom
- Employees
- YCBD N/A
- NCNA N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- NCNA Health Care
- Exchange
- YCBD Nasdaq
- NCNA Nasdaq
- Market Cap
- YCBD 7.8M
- NCNA 6.6M
- IPO Year
- YCBD N/A
- NCNA 2017
- Fundamental
- Price
- YCBD $0.75
- NCNA $2.87
- Analyst Decision
- YCBD Strong Buy
- NCNA
- Analyst Count
- YCBD 1
- NCNA 0
- Target Price
- YCBD $2.00
- NCNA N/A
- AVG Volume (30 Days)
- YCBD 147.7K
- NCNA 483.1K
- Earning Date
- YCBD 08-14-2025
- NCNA 08-20-2025
- Dividend Yield
- YCBD N/A
- NCNA N/A
- EPS Growth
- YCBD N/A
- NCNA N/A
- EPS
- YCBD N/A
- NCNA N/A
- Revenue
- YCBD $19,026,064.00
- NCNA N/A
- Revenue This Year
- YCBD $0.37
- NCNA N/A
- Revenue Next Year
- YCBD $4.95
- NCNA N/A
- P/E Ratio
- YCBD N/A
- NCNA N/A
- Revenue Growth
- YCBD N/A
- NCNA N/A
- 52 Week Low
- YCBD $0.59
- NCNA $2.78
- 52 Week High
- YCBD $6.54
- NCNA $1,650.00
- Technical
- Relative Strength Index (RSI)
- YCBD 46.69
- NCNA 29.04
- Support Level
- YCBD $0.71
- NCNA $2.78
- Resistance Level
- YCBD $0.80
- NCNA $3.60
- Average True Range (ATR)
- YCBD 0.07
- NCNA 0.28
- MACD
- YCBD 0.01
- NCNA 0.32
- Stochastic Oscillator
- YCBD 77.29
- NCNA 7.20
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.